PBMC-derive eNK cells was armed and promoted CAR-like response against tumors through armed with 16Fc21, a novel bispecific fusion protein for NK cells
Yangyang Li, Yehai Wang, Ximeng Zhang, Yan Fan, Lina Pan, Jing Wu, Weihua Xiao · 2026
Read PBMC-derive eNK cells was armed and promoted CAR-like response against tumors through armed with 16Fc21, a novel bispecific fusion protein for NK cells by Yangyang Li, Yehai Wang, Ximeng Zhang, Yan Fan, Lina Pan, Jing Wu, Weihua Xiao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582660.txt.
Description
Yangyang Li and co-authors arm natural killer cells with a designer fusion protein to attack tumors without gene editing, in a 2026 study. Killer cells from blood donors are promising cancer fighters. Editing their genes is slow and costly, though. Solid tumors also resist them more than blood cancers do. A bolt-on weapon could skip the editing step.
Their protein fuses an immune growth signal with a grip for the killer cell's trigger. It switches the cells on and steers them like a CAR therapy does. Lab tests showed stronger activation and tumor killing. The armed cells kept a CAR-like focus on targets. Cell therapy makers gain a simpler manufacturing path. Solid tumor trials are the obvious next test.
Catalog record
| CREATOR | Yangyang Li, Yehai Wang, Ximeng Zhang, Yan Fan, Lina Pan, Jing Wu, Weihua Xiao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |